ClinicalTrials.gg
CompletedNCT07756203Updated Nov 3, 2026

PMT Versus IASTM in Subacromial Impingement Syndrome

An interventional study of Percussion massage therapy device and Instrument-assisted soft tissue mobilization device in Impingement Syndrome, Impingement Shoulder and Shoulder Pain, sponsored by Emre DANSUK. Completed at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Emre DANSUK · Not applicable, Interventional, and Treatment

Updated Nov 3, 2026Now CompletedEnrollment updated+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 69 studies in Shoulder Impingement Syndrome with a site in Turkey — 12 open to participants now, 14 under way, none of them phase 3. Shoulder Impingement Syndrome · Turkey.

Enrollment
40th of 55
42 · median 48
Started
2026
with 5 others
No phase
54 of 69
8 open now
Registered
68th of 69
by date
Lead sponsor
2 of 69
Emre DANSUK

Among the 69 studies in Shoulder Impingement Syndrome with a site in Turkey, this one is the 40th largest by enrollment of the 55 interventional ones, is one of 6 that started in 2026, is one of 54 with no phase, and was the 68th registered.

By phase

69 studies; the count open now beside each. This study's row is marked.

No phasethis study54 · 8 open
Observational14 · 4 open
Phase 41 · 0 open

By the year they started

First in 2013; this study’s year is marked. 6 started in 2026.

Size and results

Median enrollment 48 across the 55 interventional studies, 77 across the 14 observational. Of the 52 that completed or were terminated, 0 (0%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 69 studies in Shoulder Impingement Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

This assessor-blinded, three-arm, parallel-group randomized controlled trial will investigate the additional effects of percussion massage therapy and instrument-assisted soft tissue mobilization in individuals with subacromial impingement syndrome. Forty-eight participants aged 40-60 years with clinically and magnetic resonance imaging-confirmed subacromial impingement syndrome will be randomly allocated in a 1:1:1 ratio to conventional physiotherapy, percussion massage therapy plus conventional physiotherapy, or instrument-assisted soft tissue mobilization plus conventional physiotherapy.

All groups received a standardized four-week conventional physiotherapy programme. Participants in the percussion massage therapy and instrument-assisted soft tissue mobilization groups additionally received their respective interventions three times per week for four weeks. Outcomes were evaluated at baseline and immediately after the four-week intervention. The primary outcome was shoulder joint position sense during flexion and abduction. Secondary outcomes were shoulder range of motion, resting and activity-related pain, upper-extremity disability, and rotator cuff-related quality of life.

Read the detailed description

Subacromial impingement syndrome is commonly associated with shoulder pain, limitations in range of motion, functional disability, and impaired sensorimotor control. Exercise-based rehabilitation is considered a primary component of conservative management. Percussion massage therapy and instrument-assisted soft tissue mobilization are frequently used as adjunct soft-tissue interventions; however, comparative evidence regarding their additional effects in individuals with subacromial impingement syndrome remains limited.

This study will be conducted as a parallel-group, assessor-blinded randomized controlled trial with a 1:1:1 allocation ratio. Forty-eight eligible participants will be randomly allocated to one of three groups: conventional physiotherapy, percussion massage therapy plus conventional physiotherapy, or instrument-assisted soft tissue mobilization plus conventional physiotherapy.

The randomization sequence will be computer-generated using Randomizer.org by an independent researcher who will not be involved in participant recruitment, intervention delivery, or outcome assessment. Because of the nature of the interventions, blinding of participants and treating physiotherapists will not be possible. Outcome assessments will be conducted by an independent physiotherapist who will be blinded to group allocation. Statistical analyses will be performed by a biostatistician who will be blinded to the coded group assignments.

All participants will receive a standardized conventional physiotherapy programme for four weeks. Participants assigned to the percussion massage therapy and instrument-assisted soft tissue mobilization groups will additionally receive the corresponding soft-tissue intervention three times per week for four weeks.

Outcome assessments will be performed at baseline and immediately after completion of the four-week intervention. The primary outcome will be shoulder joint position sense during flexion and abduction. Secondary outcomes will include shoulder range of motion, resting and activity-related pain, upper-extremity disability, and rotator cuff-related quality of life.

03

Conditions studied

  • Impingement Syndrome
  • Impingement Shoulder
  • Shoulder Pain

Keywords

  • Subacromial Impingement Syndrome
  • Shoulder Pain
  • Instrument-Assisted Soft Tissue Mobilization (IASTM)
  • Percussion Massage Therapy
  • Physiotherapy
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 40 to 60 years.
  • Diagnosis of subacromial impingement syndrome confirmed by clinical examination and -magnetic resonance imaging.
  • Positive Neer test.
  • Positive Hawkins-Kennedy test.
  • Positive painful arc test.
  • Shoulder symptoms persisting for at least one month.
  • Ability and willingness to participate in the assessment and intervention programme.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Previous surgery involving the affected upper extremity.
  • Inflammatory joint disease.
  • Shoulder osteoarthritis.
  • Rheumatic disease.
  • Malignant or benign tumour affecting the shoulder region or upper extremity.
  • Open wound or active infection in the shoulder region.
  • Inability to tolerate vibration-based therapy.
  • Inability to comply with the study protocol or intervention programme.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Percussion Massage Therapy Plus Conventional Physiotherapy

    Participants will receive the standardized conventional physiotherapy programme for four weeks and will additionally receive percussion massage therapy three times per week for four weeks.

    Device: Percussion massage therapy device · Other: Conventional Physiotherapy

  • Experimental
    IASTM Plus Conventional Physiotherapy

    Participants will receive the standardized conventional physiotherapy programme for four weeks and will additionally receive instrument-assisted soft tissue mobilization three times per week for four weeks.

    Device: Instrument-assisted soft tissue mobilization device · Other: Conventional Physiotherapy

  • Active comparator
    Conventional Physiotherapy

    Participants will receive a standardized, supervised conventional physiotherapy programme five sessions per week for four weeks.

    Other: Conventional Physiotherapy

Interventions

  • DevicePercussion massage therapy device

    Percussion massage therapy will be administered using a handheld Hypervolt device (Hyperice, California, USA) at 33 Hz, corresponding to level 2 of the device. A flat-head attachment will be used to provide uniform contact with the treated tissues. The intervention will be applied to the deltoid, supraspinatus, infraspinatus, and teres minor muscles along their anatomical fibre orientation. Each muscle will be treated for three minutes using controlled longitudinal strokes applied alternately in proximal-to-distal and distal-to-proximal directions. The intervention will last 12 minutes per session and will be administered by the same licensed physiotherapist three times per week for four weeks. It will be provided in addition to the 30-minute conventional physiotherapy programme, resulting in a total session duration of 42 minutes.

    Also known as: Hypervolt Percussion Massage Device

  • DeviceInstrument-assisted soft tissue mobilization device

    Instrument-assisted soft tissue mobilization will be administered to the deltoid, supraspinatus, infraspinatus, and teres minor muscles three times per week for four weeks. All applications will be performed by the same licensed physiotherapist. Standardized sweep and brush stroke techniques will be applied at an approximate treatment angle of 45° according to the anatomical fibre orientation of each muscle. For each muscle, 90 seconds of parallel strokes will be followed by 90 seconds of perpendicular strokes using controlled sweeping movements. The intervention will last three minutes per muscle and 12 minutes per session. It will be provided in addition to the 30-minute conventional physiotherapy programme, resulting in a total session duration of 42 minutes.

    Also known as: IASTM

  • OtherConventional Physiotherapy

    Participants will receive supervised conventional physiotherapy from a licensed physiotherapist five times weekly for four weeks. Each standard 30-minute session will include 20 minutes of TENS to the symptomatic shoulder at 100 Hz and 10 minutes of exercise. Exercises will comprise wand-assisted shoulder movements, Codman pendulum exercises, active and passive stretching, finger-ladder exercises, and elastic-band strengthening for flexion, abduction, extension, and internal and external rotation. Exercises will be performed for 10 repetitions per set, with resistance progressed according to pain, function, and tolerance. To match treatment duration and therapist contact, the control group will perform an additional standardized 12-minute exercise block during three sessions weekly, including one extra set of range-of-motion and resistance exercises. Sessions will therefore last 42 minutes on three days and 30 minutes on two days weekly.

06

What researchers measure

Primary outcomes

  1. Change in Shoulder Joint Position Sense Error

    Shoulder joint position sense will be assessed using a digital goniometer at target positions of 60° of shoulder flexion and 60° of shoulder abduction. The affected shoulder will be passively positioned at the target angle, and the participant will be allowed up to 10 seconds to memorize the position. The arm will then be returned to the neutral position, and the participant will be asked to actively reproduce the target position with their eyes closed. The absolute angular difference between the target position and the reproduced position will be calculated in degrees. Three trials will be conducted for flexion and three trials for abduction, and the mean absolute error for each direction will be used in the analysis. Lower values will indicate greater joint position sense accuracy.

    Time frame: Baseline and immediately after the 4-week intervention

Secondary outcomes

  1. Change in Shoulder Range of Motion

    Active shoulder range of motion will be measured in degrees using a digital goniometer under standardized assessment conditions. Shoulder flexion, abduction, internal rotation, and external rotation will be assessed. Higher values will represent greater shoulder range of motion.

    Time frame: Baseline and immediately after the 4-week intervention

  2. Change in Resting and Activity-Related Shoulder Pain

    Resting and activity-related shoulder pain intensity will be assessed separately using a 10-centimetre Visual Analog Scale. The scale will be anchored by 0, indicating no pain, and 10, indicating the worst imaginable pain. Participants will mark their pain intensity on the scale, and the distance from the zero anchor will be measured in centimetres. Lower scores will indicate lower pain intensity.

    Time frame: Baseline and immediately after the 4-week intervention

  3. Change in Upper-Extremity Disability

    Upper-extremity disability will be assessed using the Disabilities of the Arm, Shoulder, and Hand questionnaire. The questionnaire contains 30 items and generates a total score ranging from 0 to 100. Higher scores will indicate greater upper-extremity disability, whereas lower scores will indicate better function.

    Time frame: Baseline and immediately after the 4-week intervention

  4. Change in Rotator Cuff-Related Quality of Life

    Rotator cuff-related quality of life will be assessed using the Rotator Cuff Quality of Life questionnaire. The questionnaire contains 34 items covering physical symptoms, work, daily activities, social functioning, and emotional well-being. Scores will be expressed on a scale from 0 to 100, with higher scores indicating better rotator cuff-related quality of life.

    Time frame: Baseline and immediately after the 4-week intervention

07

Study locations

1 site
  • Istanbul Medipol University
    Istanbul, Beykoz 34815, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the published article will be made available upon reasonable request to the corresponding author for scientifically sound research purposes. Data access will be subject to approval of the proposed use and completion of an appropriate data-sharing agreement, in accordance with institutional policies and applicable ethical requirements. Supporting Information: Study Protocol Time Frame: Beginning immediately after publication and available for five years. Access Criteria: URL:

Supporting information: Study protocol

Time frame: Beginning immediately after publication and available for five years. Access Criteria: URL:

Access criteria: Data will be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the corresponding author and will require institutional approval and a signed data-sharing agreement. Data will be provided solely for the purposes specified in the approved proposal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2026 to primary completion in Nov 2026, 2 months.

Of 170 non-industry interventional studies with no phase under Shoulder Impingement Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's 2 months is below that.

Counting every sponsor, half of 172 studies reached it within 12 months; a quarter within 5 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 10, 2026
StartActual
Aug 10, 2026
Primary completionActual
Nov 1, 2026was Oct 2026
CompletionActual
Nov 1, 2026was Oct 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Primary completion
Oct 20, 2026→Nov 1, 2026
Oct 21, 2026
Study completion
Oct 20, 2026→Nov 1, 2026
Oct 21, 2026
Show all 2 updates
  1. Nov 3, 2026
    Recruiting→Completed
    + 4 other changes: verification date, date precision, contact details and site details
  2. Oct 21, 2026
    Primary completion Oct 20, 2026→Nov 1, 2026
    Study completion Oct 20, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07756203
Lead sponsor
Emre DANSUK
Responsible party
Emre DANSUK (Principal Investigator, Medipol University) — Sponsor-investigator
First posted
Aug 10, 2026
Start date
Aug 10, 2026
Primary completion
Nov 1, 2026
Completion
Nov 1, 2026
Last update
Nov 3, 2026

Study contacts

Emre DANSUK, PhD
principal investigator · Medipol University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion